Aclarion, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
ACON$1.60-8.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders' Equity/(Deficit)
| Series A · Series B · Series C | ||||||||
|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Preferred Stock · Preferred Stock | ||||||||
| Shares · Value · Shares · Value · Shares · Value | ||||||||
| Balance, December 31, 2023 | – | $– | – | $– | – | $– | ||
| Share-based compensation | – | – | – | – | – | – | ||
| Issuance of common stock and warrants related to public offering, net issuance costs | – | – | – | – | – | – | ||
| Issuance of common shares - equity line | – | – | – | – | – | – | ||
| Public offering and equity line issuance costs | – | – | – | – | – | – | ||
| Issuance of common shares - debt for equity exchange | – | – | – | – | – | – | ||
| Issuance of commitment shares - note financing | – | – | – | – | – | – | ||
| Issuance of common shares related to restricted stock units | – | – | – | – | – | – | ||
| Cashless exercise of pre-funded warrants | – | – | – | – | – | – | ||
| Round up convention related to reverse stock split | – | – | – | – | – | – | ||
| Net loss | – | – | – | – | – | – | ||
| Balance, March 31, 2024 | – | $– | – | $– | – | $– | ||
| Balance, December 31, 2024 | – | $– | 930 | $ | * | 874 | $ | * |
| Share-based compensation | – | – | – | – | – | – | ||
| Registered Direct offering of commons stock | – | – | – | – | – | – | ||
| Public offering of common stock and warrants | – | – | – | – | – | – | ||
| Common stock issuance cost | – | – | – | – | – | – | ||
| Redemption of B series preferred stock | – | – | (930) | * | – | – | ||
| Conversion of C-series preferred stock to common stock | – | – | – | – | (874) | * | ||
| Exercise of C-series warrants | – | – | – | – | – | – | ||
| Warrant amendment | – | – | – | – | – | – | ||
| Alternative cashless exercise of B warrants | – | – | – | – | – | – | ||
| Round-up conversion related to reverse stock splits | – | – | – | – | – | – | ||
| Net loss | – | – | – | – | – | – | ||
| Balance, March 31, 2025 | – | $– | – | $– | – | $– | ||
** Rounds to less than one share or $1*
(continued)
Condensed Statements of Changes in Stockholders' Equity (Deficit)
(continued)
| Common Stock · Paid-In · Accumulated | ||||||
|---|---|---|---|---|---|---|
| Shares · Value · Capital · Deficit · Total | ||||||
| Balance, December 31, 2023 | 91 | $ | * | $43,553,532 | $(44,281,526) | $(727,995) |
| Share-based compensation | – | – | 85,827 | – | 85,827 | |
| Issuance of common stock and warrants related to public offering | 572 | * | 3,001,496 | – | 3,001,496 | |
| Issuance of common shares - equity line | 50 | * | 1,449,532 | – | 1,449,532 | |
| Public offering and equity line issuance costs | – | – | (709,211) | – | (709,211) | |
| Issuance of common shares - debt for equity exchange | 71 | * | 1,771,606 | – | 1,771,606 | |
| Issuance of commitment shares - note financing | 1 | * | 33,297 | – | 33,297 | |
| Issuance of common shares related to restricted stock units | * | * | * | – | – | |
| Cashless exercise of pre-funded warrants | * | * | – | – | – | |
| Round up convention related to reverse stock split | 4 | * | – | – | – | |
| Net loss | – | – | – | (2,399,102) | (2,399,102) | |
| Balance, March 31, 2024 | 791 | $ | * | $49,186,078 | $(46,680,628) | $2,505,450 |
| Balance, December 31, 2024 | 1,370 | $ | * | $52,232,368 | $(51,262,311) | $970,057 |
| Share-based compensation | – | – | 55,897 | – | 55,897 | |
| Registered Direct offerings of common stock | 19,144 | * | 5,167,927 | – | 5,167,927 | |
| Public offering of common stock and warrants | 16,048 | * | 14,554,544 | – | 14,554,544 | |
| Common stock issuance costs | – | – | (2,101,282) | – | (2,101,282) | |
| Redemption of Series B preferred stock | – | – | (1,213,590) | – | (1,213,590) | |
| Conversion of C-series preferred stock to common stock | 687 | * | – | – | – | |
| Exercise of C-series warrants | 629 | * | 336,441 | – | 336,441 | |
| Warrant amendment | – | – | 48,087 | – | 48,087 | |
| Alternative cashless exercise of B warrants | 544,299 | 5 | (5) | – | – | |
| Round-up conversion related to reverse stock splits | 161 | * | – | – | – | |
| Net loss | – | – | – | (2,037,436) | (2,037,436) | |
| Balance, March 31, 2025 | 582,338 | $6 | $69,080,386 | $(53,299,747) | $15,780,645 | |
| * | Rounds to less than one share or $1 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.